Semaglutide

September 2, 2026 · 2 min read

Semaglutide: what the STEP 1 trial and its follow-ups reported

A research overview of semaglutide 2.4 mg, the GLP-1 receptor agonist, based on the STEP 1 randomized trial and later work on maintenance and withdrawal.

Semaglutide · Metabolic research